Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recombinant interferon (IFN) may be useful in the treatment of HIV. However, the high doses of IFN necessary to keep HIV under control limit its use due to toxic side effects. The purpose of this study is to test the safety and tolerability of weekly recombinant pegylated interferon (PEG-IFN) alfa-2a in HIV infected people who are currently on antiretroviral therapy (ART) interruption or who have not started taking anti-HIV drugs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection

NCT00594880

HIV Infections

COMPLETED PHASE2

Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2

NCT00002017

HIV Infections

COMPLETED NA

The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine

NCT00001112

HIV Infections

COMPLETED PHASE1

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals

NCT00000664

HIV Infections

COMPLETED PHASE1

Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children

NCT00000761

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

IFN is an immune response enhancer and is produced in the body in response to viral infection. PEG-IFN may have less harmful side effects than non-pegylated IFN. Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment. PEG-IFN alfa-2a has demonstrated potentially useful antiviral properties in HIV treatment; however, due to the high doses that must be administered to maintain viral suppression, toxicity (especially to the blood) is a concern. This study will evaluate the safety, tolerability, and antiretroviral activity of PEG-IFN alfa-2a in HIV infected patients who have received ART in the past but are currently off ART or who are ART naive.

The study will last 18 weeks. Participants will receive weekly injections of 180 mcg PEG-IFN alfa-2a at the clinic for 12 weeks. After Week 12, participants will be followed off-treatment until Week 18. Physical exams will be performed weekly. Blood collection to monitor viral load, PEG-IFN alfa-2a serum levels, and CD4 and CD8 counts will be conducted at selected weeks during the study. Filgrastim will be given to patients who exhibit neutropenic toxicity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Participants will receive weekly injections of 180 mcg PEG-IFN alfa-2a at the clinic for 12 weeks. After Week 12, participants will be followed off-treatment until Week 18.

Group Type EXPERIMENTAL

Pegylated interferon alfa-2a

Intervention Type DRUG

Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pegylated interferon alfa-2a

Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV infected
* CD4 count of 300 cells/ml or greater within 30 days of study entry
* HIV viral load of 5000 copies/ml or greater within 30 days of study entry
* Received ART previously but have currently interrupted treatment within 12 weeks prior to study entry OR ART naive
* Willing to delay initiation or re-initiation of antiretroviral medications for the duration of the study
* Agree to use acceptable forms of contraception

Exclusion Criteria

* Previous use of interferon alfa
* Known allergy or sensitivity to PEG-IFN alfa-2a or its formulation
* Active drug or alcohol abuse that would interfere with the study
* Acute therapy for a serious infection within 30 days of study entry
* Use of non-protocol-specified immunomodulatory therapy within 60 days of study entry
* Active immunization within 30 days of study entry
* History of severe psychiatric disease such as major depression, suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to psychiatric disease
* History of poorly controlled thyroid disease, including history of elevated thyroid stimulating hormone (TSH) levels with elevated antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease
* History of clinically significant heart disease that could be worsened by acute anemia
* History of severe seizure disorder or current anticonvulsant use
* Hepatitis C antibody positive within 60 days prior to study entry
* Hepatitis B surface antigen positive within 60 days prior to study entry
* Known sensitivity to E. coli derived products, such as filgrastim
* Any past evidence of chronic liver disease
* Any past or current evidence of immunologically-mediated disease
* Evidence of chronic pulmonary disease
* Severe eye problems due to diabetes, hypertension, cytomegalovirus infection, or macular degeneration
* History of major organ transplantation with an existing functional graft
* History or other evidence of severe illness, cancer, or other conditions that would make the patient unsuitable for the study
* Hemoglobin abnormalities or any other cause of or tendency for breakdown of red blood cells
* Any medical condition that would prevent successful completion of the study
* Use of certain medications
* Pregnant or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No